10 Takeover Targets to Watch This Fall
Pace of Biopharma M&A Slows from First Half Stampede of Deals
Marijuana Use in Adults Living with Sickle Cell Disease
Most States Do Not Specify Sickle Cell Disease as a Qualifying Condition for Legal Access to Marijuana
Vertex’s David Altshuler Humanizes Drug Discovery
Lessons from Vertex’s Small Molecule Drug Development Program for Cystic Fibrosis
The 100,000 Genomes Club
10 Countries Meet the Mark for National Genome Projects
For full access to this article login to GEN Select now.
RNAi Therapeutics: To the Liver ... and Beyond
RNAi Therapy Components Are Surviving Degradation, Staying Potent, and Reaching More Targets Than Ever
- As a means of perturbing gene expression—and avoiding manipulation of the genome—RNA interference (RNAi) has distinct advantages. RNAi, it must be said, is hardly unique in its ability to target individual genes. This ability is shared by RNAi with CRISPR inteference (CRISPRi), which may provide even better gene targeting ...
Not registered yet? Please fill out the form below and enjoy complimentary access to this and an exclusive collection of premium content and personalization features as a GEN Select insider. Learn More.
Get GEN Select Access Now
- Do not put any letters or characters here if you are not a spy program.